TLR-4 Aptamer Binding Extracellular Domain for Broad-Spectrum Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of broad-spectrum molecules capable of specifically binding to and inhibiting TLR-4, which are effective as therapeutic agents for a wide range of diseases and conditions related to the overexpression or overactivation of TLR-4, particularly in treating acute cardiac infarction and neuromuscular or neurodegenerative diseases.
Innovation Solution
The use of nucleic acid aptamers specifically targeting the extracellular domain of TLR-4, which are administered during or after acute cardiac infarction or neuromuscular/neurodegenerative disease onset, to reduce TLR-4 activation and alleviate associated symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs able to modulate TLR-4 are developed, then therapeutic treatment of TLR-4 mediated diseases is improved, but the scarcity of such drugs limits their broad spectrum applicability
Solution Approach 1:
The aptamer ApTOLL is designed to bind to the extracellular domain of TLR-4 with high affinity and specificity, serving as a universal antagonist that can treat multiple TLR-4 mediated diseases including acute cardiac infarction, neuromuscular diseases, and neurodegenerative conditions through a single molecular entity
2Reliability
If specific TLR-4 antagonists are developed for certain conditions, then treatment efficacy for those conditions is improved, but the number of applicable diseases remains limited
Solution Approach 1:
The aptamer ApTOLL functions as a broad-spectrum therapeutic agent that can be applied to treat multiple disease conditions including acute cardiac infarction, neuromuscular diseases, and neurodegenerative disorders by targeting the common TLR-4 pathway involved in these conditions
3Adaptability or versatility
If broad spectrum TLR-4 inhibitors are developed, then applicability to multiple diseases is improved, but specificity in binding to TLR-4 may be reduced
Solution Approach 1:
The aptamer ApTOLL is designed to target specifically the extracellular domain of TLR-4 with high binding affinity and specificity, achieving precise local action at the target site while maintaining broad spectrum therapeutic applicability across multiple disease conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively reduce infarct area, fibrosis, and necrosis, improve cardiac function, and inhibit demyelination, demonstrating therapeutic potential in treating TLR-4 mediated diseases by reducing TLR-4 activation.
Implementation Method 1
the aptamer specifically binds to an epitope on the extracellular domain of TLR-4
Data Source
AI summary
The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of a TLR-4 mediated disease or condition comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, or after pharmacological and/or surgical interventions (e.g., thrombolysis such as thrombectomy) or any combination thereof, for the treatment of ischemic (e.g., myocardial infarction or ischemic stroke), hemorrhagic (e.g., hemorrhagic stroke or hemorrhagic transformation), or neurodegenerative (e.g., multiple sclerosis) diseases or conditions. The disclosure also provides specific doses and dosage regimes.